摘要
目的:通过前瞻性随机对比研究,比较利伐沙班和伊诺肝素用于非ST段抬高急性冠脉综合征治疗的有效性及安全性。方法:入选符合本研究标准的79例非ST段抬高急性冠脉综合征患者,随机分为两组,利伐沙班组38例,利伐沙班5mg/12h口服;伊诺肝素组41例,1mg/(kg·12h)皮下注射。疗程8d。结果:住院期间利伐沙班组发生心脏不良事件8例,出血4例;伊诺肝素组发生心脏不良事件10例,出血7例。随访期间利伐沙班组发生心脏不良事件14例;伊诺肝素组发生心脏不良事件15例。两组间心脏不良事件发生率及出血发生率均无统计学差异(P>0.05)。结论:利伐沙班与伊诺肝素抗凝治疗效果相当,出血的发生率相似,该药既有效又安全。
ObjectiveThrough prospective randomized comparative study, to compare curative efficacy and safety of rivaroxa-ban and enoxaparin in treatment of non-ST segment elevation acute coronary syndrome. Methods：79 patients with non-ST segment el-evation acute coronary syndrome were randomized to rivaroxaban group （38 cases） and enoxaparin group （41 cases）. The cases in ri-varoxaban group were treated with rivaroxaban at 5mg/12h for 8 days, while those in enoxaparin group were treated with enoxaparin at1mg/ kg/12h through subcutaneous injection for 8 days. The curative efficacy and safety were observed. Results： In the hospitalization,there were 8 cases with the adverse cardiac events and 4 cases with bleeding in rivaroxaban group, however, there were 10 cases withthe adverse cardiac events and 7 cases with bleeding enoxaparin group. During the follow-up period, there were 14 and 15 cases withthe adverse cardiac events in rivaroxaban group and enoxaparin group, respectively. There were no statistical differences in the inci-dences of the adverse cardiac events and bleeding between the two groups （P〉0. 05）. Conclusions： Rivaroxaban has the similar anti-coagulation therapy effect and bleeding incidence with enoxaparin. Moreover, rivaroxaban is both safe and effective.
出处
《中国民康医学》
2014年第5期33-35,共3页
Medical Journal of Chinese People’s Health
